Trial Profile
Phase II trial of Gemzar plus paraplatin [carboplatin] (plus Herceptin [trastuzumab] in HER2+ [human epidermal growth factor receptor-2 positive] patients) in metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 17 Dec 2009 Actual end date changed from Apr 2006 to Oct 2008 as reported by ClinicalTrials.gov.
- 28 Aug 2006 Status change
- 10 Nov 2005 New trial record.